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Abstract
Background: The ambulatory arterial stiffness index (AASI) ob-
tained during ambulatory blood pressure monitoring (ABPM) has 
been cited as an independent predictor of major adverse cardiovascu-
lar events (MACEs) including cardiovascular death, stroke and wors-
ening chronic kidney disease (CKD) among mixed-sex adult popula-
tions. This study aimed to determine the relationship between AASI 
and MACE and its predictive precision in women.
Methods: This work follows the guidelines of the STROBE initiative 
for cohort studies. This was a retrospective single-center observational 
study of adult women (aged 18 - 75 years), who underwent 24-h ABPM 
for the diagnosis of hypertension or its control. The primary endpoint 
was a composite MACE of cardiovascular death, acute limb ischemia, 
stroke, acute coronary syndrome (ACS), or progression to stage V CKD.
Results: A total of 219 women aged 57.4 ± 13.3 years were followed up 
for a median (interquartile range (IQR)) of 25.5 (18.3 - 31.3) months. 
Overall, 16 (7.3%) patients suffered one or more MACE events. AASI 
was significantly higher in patients with known coronary artery disease 
(CAD), diabetes mellitus, peripheral vascular disease (PVD), heart fail-
ure, previous stroke, or transient ischemic attack (TIA). AASI was a 
significant predictor of MACE (area under the curve: 0.78; P < 0.001) 
with an optimal cut-off of ≥ 0.56. On Kaplan-Meier analysis AASI ≥ 
0.56 was significantly associated with MACE (log-rank test, P < 0.001). 
The only independent predictors of MACE on Cox proportional hazard 
analysis were diabetes mellitus, low high-density lipoprotein (HDL) 
levels, cumulative AASI values, or AASI ≥ 0.56.
Conclusions: An AASI of ≥ 0.56 is an independent predictor of 
MACE in women. A further validation study in a larger cohort of 
women is recommended.
Keywords: Ambulatory arterial stiffness index; Major adverse car-
diovascular events; Women
Introduction
Current guidelines for the management of hypertension rec-
ommend the use of 24-h ambulatory blood pressure monitor-
ing (ABPM) for the diagnosis of genuine hypertension and its 
differentiation into white-coat reactors [1-3]. Among the va-
riety of derived variables obtained on ABPM the ambulatory 
arterial stiffness index (AASI) has emerged as an increasingly 
useful, yet indirect measure, of arterial stiffness. The AASI has 
been shown to correlate strongly with pulse wave velocity and 
pulse pressure, and has the advantage over several measures of 
arterial stiffness by its low cost and fully automated acquisi-
tion [4, 5].
AASI has been associated with target organ damage and 
major adverse cardiovascular events (MACEs) including 
stroke, myocardial infarction, acute limb ischemia, cardiovas-
cular death, and worsening kidney function [6-9]. One of its 
additional advantages over other ABPM measures, as a poten-
tial cardiovascular disease (CVD) marker, is its lower vulner-
ability to short-term temporal changes in heart rate and blood 
pressure [10-12].
The data linking AASI to adverse cardiovascular out-
comes mainly relate to adults with known hypertension. De-
spite its promise, the AASI has remained largely a research 
tool in practice despite this data being made available in sev-
eral ABPM platforms. Despite accounting for approximately 
50% of adults with hypertension, women have often been un-
represented in several studies [6, 13-15]. Moreover, it has been 
reported that women have higher AASI values than men of 
similar age [5]. Hence, a further understanding of the links be-
tween AASI and cardiovascular outcomes in women needs to 
be explored in greater depth.
This study had two principal aims. The first was to exam-
ine the relationship between AASI and adverse cardiovascu-
lar events in adult women. The second aim was to determine 
whether an optimal cut-off value for AASI could be deter-
mined to improve its potential for mainstream clinical use.
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Materials and Methods
Population and design
The STROBE Initiative Guidelines for cohort studies were fol-
lowed [16]. This was a single-center retrospective observation-
al study of consecutive adult women (aged 18 - 75 years), who 
underwent 24-h ambulatory blood pressure for the diagnosis 
or hypertension or assessment of its control from the March 
1, 2017 to May 10, 2019. All tests were performed at Poole 
Hospital NHS Foundation Trust.
Patients with previous organ transplantation, persistent/
permanent atrial fibrillation, stage IV or V chronic kidney 
disease (CKD), active cancer, pregnancy, severe aortic steno-
sis, or aortic coarctation were excluded. Patients undergoing 
ABPM for the investigation of syncope with active infection 
or vasculitis or who had been hospitalised within the previous 
week were also excluded.
The primary endpoint
This was the occurrence of composite MACEs of cardiovas-
cular death, stage V CKD, and nonfatal acute limb ischemia, 
stroke, or acute coronary syndrome (ACS) [7, 9]. ACS was de-
fined in accordance with the European Society of Cardiology 
(ESC) guidelines and required the opinion of a cardiologist. 
The diagnoses of stroke and transient ischemic attack (TIA) 
were based on clinical presentation, supported by radiological 
imaging and had to be confirmed by a stroke physician. Acute 
limb ischemia was defined as a sudden decrease in limb perfu-
sion causing a potential threat to limb viability and requiring 
hospitalisation. Coronary artery disease (CAD) was defined as 
a previous myocardial infarction, percutaneous coronary an-
gioplasty/stenting, or a significant stenosis of ≥ 70% in ≥ 1 
major coronary arteries [17].
The occurrence of any MACE was censored using the hos-
pital electronic patient records, which were available for Poole 
and the neighbouring Royal Bournemouth and Christchurch 
Hospitals. Only definite or highly probable diagnoses were 
used in the ascertainment of MACE.
24-h ambulatory blood pressure measurement
This was performed on a normal weekday by means of an 
automatic ABPM (Spacelab 90207, Spacelab Healthcare, 
Hertford, UK) using an automated oscillometric cuff that was 
placed on the nondominant arm. The device was set to measure 
blood pressure and heart rate at 30 min intervals throughout a 
24-h recording period. The night-time period was defined as 
the hours of 10:01 pm to 6:00 am, and the day-time period 6:01 
am to 10:00 pm. Patients were only included if they had a min-
imum of 10 day-time and five night-time ambulatory blood 
pressure measures during the 24-h recording period [18].
The AASI was calculated, as 1 minus the regression slope 
of the diastolic to systolic blood pressure over the 24-h record-
ing period [19]. The AASI ranges from a value of 0 to 1 with 
higher readings suggestive of stiffer arteries. The morning 
surge index was defined as 100 × (1 - (night average/morn-
ing average)). For this calculation the “morning” average = 
mean of all systolic values within the first 2 h after waking and 
the night average as the average of all values that within ± 30 
min of the minimum time [20, 21]. The reported inter-observer 
paired differences in 24 h AASI recordings (2 - 5 weeks apart; 
n = 423) have been reported to be negligible (mean difference 
≤ 0.01) with repeatability coefficients of 50-60% suggesting 
modest repeatability [22, 23].
Blood tests
Venous blood for the measurement of lipid profile, full blood 
count, renal function, and glycated hemoglobin (HbA1c) were 
analyzed in our hospital laboratory and within 3 months of the 
ABPM measurements. The estimated glomerular filtration rate 
(eGFR) was calculated according to the Modification of Diet 
in Renal Disease (MDRD) Study equation based on patient 
age, sex, and ethnicity [24].
Ascertainment of clinical events
All patients were followed up for a minimum of 12 months or 
until death.
Ethical approval
This study and its experimental protocol were approved by the 
Poole Hospital Clinical Research and Innovation Department 
and the West of Scotland Research Ethics Committee (REC 
reference: 20/WS/0097); and the study was conducted in com-
pliance with the ethical standards of the responsible institution 
on human subjects as well as with the Helsinki Declaration.
Statistical analysis
Statistical analyses were performed with SPSS 26.0 (SPSS, 
Chicago, IL, USA) and GraphPad Prism version 6.07 for Win-
dows (GraphPad Software, San Diego, CA, USA). Data inspec-
tion and the D’Agostino-Pearson normality test were used to 
assess normality of all continuous data. Continuous data were 
presented as mean ± standard deviation, except for highly 
skewed data where median and interquartile ranges were re-
ported. Two group comparisons of continuous data were com-
pared using an unpaired t-test or the Mann-Whitney U test for 
parametric and nonparametric data respectively. Categorical 
data were examined using Fisher’s exact tests and Chi-square 
tests as appropriate. Correlations were investigated using Pear-
son and Spearman rank coefficients (± 95% confidence interval 
(CI)) for parametric and nonparametric data, respectively. Only 
notable correlations with a coefficient r ≥ 0.20 were reported.
A receiver operating characteristic (ROC) curve analy-
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sis was used to determine the optimal cut-off value of AASI 
to predict MACE. Kaplan-Meier analysis with log-rank test 
was conducted to compare the MACE-free survival using this 
AASI cut-off. Multivariate Cox regression analysis used to es-
timate the adjusted hazard ratio (HR) and 95% CI for the uni-
variate predictors (P < 0.10) of the primary endpoint and de-
termine the independent MACE predictors. Where there were 
multiple endpoints during follow-up, the time to the first event 
was considered for analysis of MACE. A P value of < 0.05 was 
considered statistically significant.
Sample size calculations
Estimation of our sample size for sufficient power was per-
formed using a proprietary sample size calculator (GraphPad 
StatMate version 2.00 for Windows). This was based on pre-
vious studies investigating the relationship of the AASI and 
cardiovascular events (cardiovascular death and nonfatal myo-
cardial infarction and stroke) [6, 8, 9, 19].
We calculated that a sample size of at least 160 patients 
would have ≥ 80% power to detect a difference between AASI 
means (MACE vs. non-MACE group) of 0.15 at a significance 
level (alpha) of 0.05 (two-tailed).
Results
A total of 219 women were included. Their average age was 
57.4 ± 13.3 years and the median duration of follow-up was 25.5 
(18.3 - 31.3) months (Table 1). A total of 149 (68.0%) patients 
had known previous CVD (CAD, previous stroke/TIA, periph-
eral vascular disease (PVD), hypertension, or heart failure).
Overall, 16 (7.3%) patients suffered one or more MACE 
events. This included two cardiovascular deaths, four stroke/
TIAs, five ACSs, four episodes of acute limb ischemia, and 
one case of CKD stage V. The univariate predictors of the pri-
mary endpoint were a history of diabetes mellitus, PVD, older 
age, decreased eGFR and high-density lipoprotein (HDL) cho-
lesterol levels, use of statins or α-blockers (Table 1). Among 
the 24-h ABPM variables, in AASI, the 24-h, day-time and 
night-time pulse pressures, and night-time systolic blood pres-
sure were also greater among the patients who had suffered a 
MACE event (Table 2).
AASI was significantly higher in patients with known 
CAD (0.53 ± 0.02 vs. 0.43 ± 0.01; P = 0.004), diabetes mel-
litus (0.50 ± 0.03 vs. 0.44 ± 0.01; P = 0.03), PVD (0.61 ± 0.19 
vs. 0.45 ± 0.16; P = 0.045), heart failure (0.56 ± 0.13 vs. 0.45 
± 0.16; P = 0.03), stroke or TIA (0.53 ± 0.14 vs. 0.44 ± 0.17; 
P = 0.03) and with a previous history of CVD (0.46 ± 0.17 vs. 
0.41 ± 0.16; P = 0.03).
AASI significantly correlated with age (r = 0.49; 95% CI: 
0.39 to 0.59; P < 0.0001), HbA1c (r = 0.30; 0.15 to 0.43; P < 
0.0001), 24-h average systolic blood pressure (r = 0.34; 0.22 
to 0.46; P < 0.0001), pulse pressure (r = 0.56; 0.45 to 0.64; 
P < 0.0001), day-time systolic blood pressure (r = 0.29; 0.16 
to 0.41; P < 0.0001) , and pulse pressure (r = 0.56; 0.46 to 
0.65; P < 0.0001), night-time systolic blood pressure (r = 0.45; 
0.33 to 0.55; P < 0.0001), mean arterial pressure (r = 0.31; 
0.18 to 0.42; P < 0.0001) and pulse pressure (r = 0.50; 0.39 to 
0.60; P < 0.0001). AASI inversely correlated with 24-h heart 
rate (r = -0.25; -0.37 to -0.11; P = 0.0002), systolic (r = -0.41; 
-0.51to -0.29; P < 0.0001), diastolic (r = -0.54; 0.63 to -0.43; P 
< 0.0001) and mean arterial pressure (r = -0.48; -0.58 to -0.37; 
P < 0.0001) dipping, day-time diastolic blood pressure (r = 
-0.25; -0.37 to -0.12; P < 0.0001), estimated as well as eGFR 
(-0.23; -035 to -0.1; P = 0.0008).
Receiver operator characteristic for AASI to predict 
MACE
On ROC analysis AASI significantly differentiated the pa-
tients with MACE (area under the curve: 0.78; P < 0.001). The 
optimal cut-off value for predicting MACE was an AASI of ≥ 
0.56 (Fig. 1). The patients (n = 62) with an AASI ≥ 0.56 were 
significantly older (+9.2 ± 1.9 years; P < 0.0001) with a lower 
eGFR (mean difference -4.7 ± 2.3 mL/min/1.73 m2; P = 0.04) 
compared with patients with lower AASI values (< 0.56).
Kaplan-Meier analysis
Kaplan-Meier analysis was performed to compare the MACE-
free survival rates of patients with an AASI ≥ 0.56 vs. < 0.56. 
Patients with an AASI ≥ 0.56 had a higher incidence of MACE 
(log-rank test, P < 0.001) (Fig. 2).
Independent predictors of MACE
Cox multivariate proportional hazard model was constructed 
to determine the independent predictors of MACE. This model 
included the univariate predictors of MACE along with the 
borderline predictors (P ≤ 0.1) (Table 3). The independent pre-
dictors of MACE were diabetes mellitus, lower HDL levels, 
and an AASI of ≥ 0.56 (Table 3). AASI as a continuous vari-
able in the same model (instead of an AASI ≥ 0.56) was also 
a significant independent predictor (HR: 1.07; 1.02 - 1.1; P = 
0.008). None of the other 24-h blood pressure variables used 
instead of AASI (to prevent collinearity) were significantly as-
sociated with MACE on multivariate analysis.
Discussion
This was the first study to investigate the relationship between 
AASI and MACE events in an unselected population of adult 
women. We found that both increasing AASI values and an 
AASI of ≥ 0.56 were independent predictors of MACE.
The AASI is reported to be an indirect measure of arterial 
stiffness. AASI has been shown to be significantly correlated 
with pulse wave velocity, central pulse and blood pressure as 
well as both central and peripheral arterial augmentation index 
[5, 25]. There is accumulating evidence supporting an associa-
tion between the AASI and adverse cardiovascular events in-
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cluding cardiovascular death, ACS, stroke and worsening renal 
function [7, 8, 19, 25]. Moreover, the AASI has been shown 
to independently predict cardiovascular mortality even among 
normotensive subjects [19]. Our results validate this previous 
research. One-third of our included patients were not known 
to have hypertension and the average day-time blood pressure 
at 135.8 ± 16.7 mm Hg was only just above the threshold for 
the diagnosis of hypertension. We observed a significant cor-
relation between pulse pressure and AASI with higher AASI 
in patients with a higher burden of cardiovascular risk factors.
It has been previously reported that AASI also correlates 
with increasing age and 24-h mean arterial and systolic blood 
pressure [5]. Our data support this and further validate our 
findings. We also observed a significant association between 
AASI and a wide range of atherosclerotic risk factors linked 
to the development of increased arterial stiffness, atheroscle-
rosis, and CVD. We noted that AASI correlated with increased 
HbA1c with significantly higher values in patients with dia-
betes mellitus, PVD, previous stroke/TIA, heart failure and 
CAD, legitimising its role as a cardiovascular risk marker. Our 
observed correlation between AASI and decreased eGFR and 
lower eGFR among patients with an elevated AASI of ≥ 0.56 
again supports previous work. Mule et al also reported similar 
findings among a cohort of 143 untreated hypertensive sub-
jects [26]. More recently, Erikson et al found AASI to be an 
independent risk factor for accelerated age-related temporal 
decline in GFR among a general middle-aged population [27].
In this study, both cumulative AASI values and an AASI ≥ 
Table 1.  Baseline Demographics and Clinical Characteristics of the Total Cohort and Patients With and Without MACE
Characteristic Full cohort No MACE MACE P value
Number 219 203 16
Age 57.4 ± 13.3 57.0 ± 13.50 63.50 ± 10.4 0.047
Body mass, kg 76.6 ± 17.9 81.80 ± 22.23 81.0 ± 22.8 0.32
Body mass index, kg/m2 29.2 ± 6.7 29.1 ± 6.6 31.1 ± 7.6 0.26
Caucasian 213 (97.3%) 197(97.0%) 15 (100%) 0.99
Ischemic heart disease 24 (4.4%) 21 (10.3%) 3 (18.8%) 0.39
Diabetes mellitus 27 (12.3%) 20 (9.8%) 8 (50.0%) 0.0002
Previous stroke or TIA 11 (5.0%) 9 (4.4%) 2 (12.5%) 0.19
Heart failure 7 (3.2%) 5 (2.5%) 2 (12.5%) 0.09
Peripheral vascular disease 4 (1.8%) 1 (0.5%) 3 (20%) 0.001
Hypertension 146 (66.7%) 132 (65.0%) 14 (87.5%) 0.10
Smoking status
  Current/ex 85 (40.7%) 85(41.9%) 4 (25%) 0.49
  Never 130 (59.3%) 118 (58.1% 12 (75%)
Medication
  ACE-I/ARB 102 (46.6%) 92 (45.3%) 10 (62.5%) 0.20
  Calcium channel blocker 80 (36.5%) 72 (35.5%) 8 (50.0%) 0.28
  Beta blockers 51 (23.3%) 45 (22.2%) 6 (37.5%) 0.22
  Diuretics 36 (16.4%) 32 (15.8%) 4 (25.0%) 0.31
  Alpha blockers 20 (9.1%) 16 (7.9%) 4 (25.0%) 0.045
  Statins 63 (28.8%) 54 (26.6%) 9 (56.3%) 0.02
  Aldosterone antagonists 8 (3.7%) 8 (3.9%) 0 (0%) 0.99
Ejection fraction, % 60.4 ± 9.32 60.4 ± 9.5 60.8 ± 7.3 0.88
Hemoglobin g/L 136.1 ± 12.8 136.3 ± 12.9 132.5 ± 11.7 0.26
Estimated glomerular filtration rate, mL/min/1.73m2 70.8 ± 15.5 71.4 ± 14.9 63.0 ± 20.4 0.037
Total cholesterol, mmol/L 5.1 ± 1.1 5.1 ± 1.1 4.8 ± 1.4 0.34
HDL cholesterol, mmol/L 1.7 ± 0.5 1.7 ± 0.5 1.3 ± 0.3 0.001
Triglycerides, mmol/L 1.5 ± 0.9 1.5 ± 0.9 1.7 ± 0.9 0.25
HbA1c 42.0 ± 14.0 41.3 ± 12.4 49.9 ± 26.1 0.44
MACE: major adverse cardiovascular event; TIA: transient ischemic attack; ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin II 
receptor blocker; HDL: high-density lipoprotein; HbA1c: glycated hemoglobin. P values refer to the results of comparison between the MACE and 
non-MACE groups only.
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0.56 were independent predictors of MACE. This defined cut-
off may have useful practical value to transform the utility of the 
AASI from a research tool to one of genuine clinical use. Further 
validation of this cut-off in additional longitudinal studies would 
be helpful to better appreciate its translational impact. It is in-
teresting that in a previous study of mixed-sex adults referred 
for ABPM for the diagnosis of hypertension, that the highest 
quintile of AASI was a value of ≥ 0.55. The authors reported 
that subjects in this highest AASI group also had the greatest 
burden of cardiovascular risk factors (diabetes, older age, histo-
ry of CVD, etc.). Unfortunately, the responsiveness of AASI to 
antihypertensive treatment has not been well demonstrated and 
appears to be marginal [28]. Consequently, its utility as a useful 
indicator of the efficacy of antihypertensive therapy and attenu-
ation of cardiovascular risk has not been demonstrated to date.
In a previous meta-analysis, Aznaouridis et al examined 
the predictive value of the AASI for adverse cardiovascular 
events [29]. They included seven longitudinal studies over a 
mean follow-up of 7.8 years. They found that an increase in the 
AASI by one standard deviation was associated with an age, 
sex and risk factor relative risk increase in total cardiovascu-
lar events (cardiovascular deaths and nonfatal cardiovascular 
events) and stroke by 15% and 30%, respectively. Interestingly, 
they observed that the AASI was a better predictor of cardio-
vascular events in women than men, emphasising the need to 
validate an AASI cut-off of 0.56 in men or in a mixed larger sex 
population. This is particularly relevant as it has been previ-
ously suggested that AASI values tend to be higher in women 
[5]. In a previous study comparing 189 women with 159 men of 
similar age (approximately 46 years), it was observed that sex 
was an independent determinant of AASI, and that AASI values 
were significantly higher in women than men (0.38 vs. 0.33). 
Furthermore, they noted that the difference was far greater in in 
hypertensive subjects (0.45 vs. 0.31; P = 0.0001).
Limitations
This study has a number of limitations that should be acknowl-
edged. This was a retrospective study. We used a broad defini-
tion of MACE. This selection of clinical events were specifi-
cally chosen prior to our data collection and were based on 
previously published data linking AASI to cardiovascular death, 
nonfatal stroke, ACS, limb ischemia and worsening renal dis-
ease. Endpoints were only adjudicated from our local hospital 
electronic records. Hence, we cannot not exclude the possibility 
Table 2.  Baseline Demographics and 24-Hour Ambulatory Blood Pressure Readings of the Full Cohort and Those With and Without 
MACE
Characteristic Full cohort No MACE MACE P value
Number of readings 29.5 ± 3.7 27.1 ± 5.3 26.8 ± 5.3 0.15
24-h ABPM averages
  Systolic blood pressure dip, mm Hg 9.6 (4.2 - 14.1) 9.6 (4.8 - 14.1) 7.5 (0.44 - 15.1) 0.16
  Diastolic blood pressure dip, mm Hg 14.1 (8.7 - 19.4) 14.1 (8.9 - 20.1) 9.2 (4.9 - 17.8) 0.09
  Mean arterial blood pressure dip, mm Hg 11.1 (5.8 - 16.4) 11.3 (6.1 - 16.6) 8.5 (1.8 - 14.2) 0.10
  Systolic blood pressure, mm Hg 132.6 ± 16.9 132.3 ± 16.9 137.3 ± 17.4 0.12
  Diastolic blood pressure, mm Hg 76.6 ± 10.8 76.9 ± 10.9 73.4 ± 8.8 0.15
  Mean arterial pressure, mm Hg 96.3 ± 11.2 96.3 ± 11.4 96.4 ± 9.2 0.86
  Pulse pressure, mm Hg 56.2 ± 14.0 55.5 ± 13.5 64.2 ± 17.7 0.02
Day-time averages
  Systolic blood pressure, mm Hg 135.8 ± 16.7 135.5 ± 16.7 139.8 ± 16.8 0.16
  Diastolic blood pressure, mm Hg 79.2 ± 10.9 79.6 ± 11.1 75.2 ± 8.0 0.13
  Mean arterial pressure, mm Hg 99.0 ± 11.2 99.1 ± 11.4 998.3 ± 8.3 0.80
  Pulse pressure, mm Hg 56.6 ± 14.1 56.0 ± 13.6 64.8 ± 18.2 0.02
Night-time averages
  Systolic blood pressure, mm Hg 123.0 ± 18.2 122.2 ± 17.8 130.8 ± 21.4 0.07
  Diastolic blood pressure, mm Hg 68.1 ± 10.4 68.2 ± 10.3 67.4 ± 11.8 0.79
  Mean arterial pressure, mm Hg 87.7 ± 11.8 87.5 ± 11.7 90.7 ± 12.9 0.30
  Pulse pressure, mm Hg 54.9 ± 10.0 54.2 ± 13.5 63.2 ± 18.5 0.02
Ambulatory arterial stiffness index 0.45 ± 0.16 0.44 ± 0.16 0.60 ± 0.15 < 0.0001
Morning surge index 0 (0 - 9.7) 0 (0 - 10.2) 0 (0 - 7.8) 0.86
ABPM: ambulatory blood pressure monitoring; MACE: major adverse cardiovascular event; TIA: transient ischemic attack; ACE-I: angiotensin con-
verting enzyme inhibitor; ARB: angiotensin II receptor blocker; HDL: high-density lipoprotein. P value refers to difference between MACE and non-
MACE groups only.
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there were undetected adverse cardiovascular events that were 
registered elsewhere. Our sample size was relatively small. 
Hence, we were not sufficiently powered to examine individual 
components of the primary endpoint. Nevertheless, this sample 
size was based on a robust power calculation and represents to 
our knowledge, the largest all-female study of AASI.
Conclusions
This was the first study to examine the relationship between 
AASI and cardiovascular events in an unselected group of 
adult women. We found that an AASI value of ≥ 0.56 to be a 
significant and potentially useful clinical risk marker for the 
detection of patients at higher risk of adverse cardiovascular 
events.
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Figure 2. Kaplan-Meier survival analysis showing the event-free survival for major adverse cardiac events in patients with an 
AASI ≥ 0.56 (red) versus < 0.56 (blue line). AASI: ambulatory arterial stiffness index.
Figure 1. Receiver operating characteristic curve of AASI for the pre-
diction of major adverse cardiac events (MACEs).
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